<p>This week, <a href="https://dk.linkedin.com/in/andreas-euvc/en" target="_blank" rel="ugc noopener noreferrer"><strong>Andreas Munk Holm</strong></a> talks with <a href="https://www.linkedin.com/in/jakimov/?originalSubdomain=lv" target="_blank" rel="ugc noopener noreferrer"><strong>Sergey Jakimov</strong></a>, Co-founder and Managing Partner at <a href="http://www.longevc.com" target="_blank" rel="ugc noopener noreferrer"><strong>LongeVC</strong></a>, a leading longevity-focused venture fund backing breakthroughs in biotech, AI-driven drug discovery, and the science of healthy aging.</p><p>From pre-seed biotech spin-outs to multi-hundred-million-dollar exits with Big Pharma, LongeVC is building the category-defining fund at the frontier of life extension. In this episode, Sergey walks us through the team’s <em>3x+ MOIC</em> track record, how LongeVC’s scientific advisory board unlocks proprietary deal flow, and why longevity and healthspan investing could be venture’s next trillion-dollar frontier.</p><p><strong>🎧 Here’s what’s covered</strong></p><ul><li><p><strong>01:15</strong> – Who is Sergey Jakimov? From biotech entrepreneur to longevity investor</p></li><li><p><strong>03:00</strong> – What is LongeVC: thesis, structure, and Fund II snapshot</p></li><li><p><strong>06:20</strong> – The market for longevity &amp; age-related disease: a $1.6 trillion opportunity</p></li><li><p><strong>09:30</strong> – Track record: Fund I’s 3x+ MOIC, 0 write-offs, 20 portfolio companies</p></li><li><p><strong>12:40</strong> – How LongeVC sources deals: scientific advisory board and AI-driven diligence</p></li><li><p><strong>15:15 </strong>– Ecosystem advantage: from nonprofits to physician networks</p></li><li><p><strong>18:00</strong> – Case study 1 – <strong>Insilico Medicine</strong>, the $1.5 billion AI-drug-discovery unicorn</p></li><li><p><strong>20:15</strong> – Case study 2 – <strong>Turn Biotechnologies</strong> and $300 million + HanAll partnership</p></li><li><p><strong>22:30</strong> – Case study 3 – <strong>Rubedo Life Sciences</strong> and Beiersdorf’s dermatology deal</p></li><li><p><strong>25:00</strong> – How pharma’s pipeline erosion fuels biotech M&amp;A</p></li><li><p><strong>28:10</strong> – Fund II: $120 million target, 20 % carry, 10-year term</p></li><li><p><strong>31:20</strong> – LP privileges: access, co-investments, and semi-annual IC observation</p></li><li><p><strong>34:00</strong> – Sergey’s vision: longevity as both moral and financial imperative</p></li></ul>